TG Therapeutics, Inc. (TGTX) Key Metrics
TGTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $8.26B
- Enterprise value
- $8.75B
- P/E (TTM)
- 19.6 10-yr median 200.2
- Forward P/E
- 25.9
- PEG ratio
- 1.61
- Price / sales
- 10.3 10-yr median 14.7
- Price / book
- 14.2 10-yr median 12.2
- EV / EBITDA
- 62.8 10-yr median 93.1
- Dividend yield
- —
- Beta
- 1.80
TGTX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTGTX valuation Price multiples at each fiscal year-end price.
TGTX returns How much profit the business earns on the capital it uses.
TGTX per-share figures Results divided by the shares outstanding at year-end.
TGTX financial health Debt, liquidity and how easily interest is covered.
TGTX efficiency & capital use Working capital cycle and where the cash goes.
TGTX valuation history
TGTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TGTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TGTX cash returned to shareholders
TGTX price vs earnings per share
TGTX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $4.81B | $4.83B | $2.54B | $1.60B | $2.51B | $6.00B | $980.9M | $309.4M | $509.0M | $228.0M |
| Enterprise value | $4.93B | $4.77B | $2.43B | $1.52B | $2.28B | $5.44B | $881.3M | $240.7M | $424.3M | $183.1M |
| P/E ratio | 10.8 | 206.4 | 200.2 | — | — | — | — | — | — | — |
| Price / sales | 7.8 | 14.7 | 10.9 | 575.2 | 375.6 | — | — | — | — | — |
| Price / book | 7.4 | 21.7 | 15.8 | 27.3 | 10.6 | 11.6 | 25.4 | 12.9 | 7.6 | 6.4 |
| EV / sales | 8.0 | 14.5 | 10.4 | 547.0 | 340.3 | — | — | — | — | — |
| EV / EBITDA | 36.7 | 95.6 | 93.1 | — | — | — | — | — | — | — |
| Earnings yield | 9.3% | 0.5% | 0.5% | −14.0% | −13.9% | −4.7% | −17.6% | −56.1% | −23.3% | −34.3% |
| Free cash flow yield | −0.5% | −0.8% | −1.2% | −11.0% | −11.8% | −3.6% | −13.6% | −41.7% | −18.4% | −27.2% |
| Dividend yield | — | — | — | — | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 1.9% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $29.81 | $30.10 | $17.08 | $11.83 | $19.00 | $52.02 | $11.10 | $4.10 | $8.20 | $4.65 |
| Per share | ||||||||||
| Revenue per share | $3.82 | $2.05 | $1.57 | $0.02 | $0.05 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | $2.77 | $0.15 | $0.09 | −$1.65 | −$2.63 | −$2.42 | −$1.96 | −$2.30 | −$1.91 | −$1.60 |
| Operating cash flow per share | −$0.15 | −$0.25 | −$0.21 | −$1.30 | −$2.24 | −$1.86 | −$1.50 | −$1.71 | −$1.51 | −$1.26 |
| Free cash flow per share | −$0.15 | −$0.25 | −$0.21 | −$1.30 | −$2.24 | −$1.86 | −$1.50 | −$1.71 | −$1.51 | −$1.26 |
| Cash per share | $0.88 | $1.94 | $1.46 | $1.19 | $2.38 | $5.25 | $1.59 | $0.91 | $1.37 | $0.92 |
| Book value per share | $4.01 | $1.39 | $1.08 | $0.43 | $1.79 | $4.50 | $0.44 | $0.32 | $1.08 | $0.73 |
| Tangible book value per share | $4.01 | $1.38 | $1.08 | $0.43 | $1.79 | $4.50 | $0.43 | $0.31 | $1.05 | $0.70 |
| Dividends per share | — | — | — | — | $0.00 | $0.00 | $0.00 | — | $0.00 | $0.00 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 |
| Debt per share | $1.62 | $1.58 | $0.75 | $0.61 | $0.60 | $0.36 | $0.46 | $0.00 | $0.00 | $0.00 |
| Shares outstanding | 161.4M | 160.3M | 148.5M | 135.4M | 132.2M | 115.3M | 88.4M | 75.5M | 62.1M | 49.0M |
| Change in shares outstanding | +0.7% | +8.0% | +9.7% | +2.4% | +14.6% | +30.5% | +17.1% | +21.6% | +26.6% | +7.4% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 102.8% | 12.2% | 11.6% | −151.4% | −92.0% | −100.1% | −551.9% | −381.2% | −230.4% | −113.9% |
| Return on invested capital (ROIC) | 26.5% | 35.0% | 118.6% | — | — | — | — | — | — | — |
| Return on assets (ROA) | 54.5% | 5.2% | 4.8% | −78.1% | −69.3% | −70.8% | −140.2% | −191.7% | −155.7% | −93.0% |
| Return on tangible assets | 42.1% | 4.1% | 3.9% | −116.1% | −91.9% | −44.7% | −106.6% | −209.5% | −123.7% | −147.1% |
| Free cash flow margin | −4.1% | −12.3% | −13.4% | — | — | — | — | — | — | — |
| Income quality (OCF / net income) | −0.06 | −1.73 | −2.48 | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $260.7M | $253.7M | $110.8M | $83.1M | $79.0M | $42.0M | $40.8M | $67,000 | $127,614 | $68,875 |
| Cash & short-term investments | $142.0M | $311.0M | $217.5M | $161.7M | $314.8M | $605.4M | $140.4M | $68.8M | $84.8M | $45.0M |
| Net debt | $118.8M | −$57.3M | −$106.7M | −$78.6M | −$235.7M | −$563.5M | −$99.6M | −$68.7M | −$84.7M | −$44.9M |
| Debt / equity | 0.40 | 1.14 | 0.69 | 1.42 | 0.33 | 0.08 | 1.06 | 0.00 | 0.00 | 0.00 |
| Debt / assets | 0.25 | 0.44 | 0.34 | 0.43 | 0.21 | 0.07 | 0.25 | 0.00 | 0.00 | 0.00 |
| Net debt / EBITDA | 0.88 | −1.15 | −4.09 | — | — | — | — | — | — | — |
| Current ratio | 4.10 | 6.25 | 5.92 | 3.16 | 5.06 | 6.99 | 1.77 | 2.03 | 3.34 | 3.01 |
| Quick ratio | 3.29 | 5.03 | 5.18 | 3.16 | 5.42 | 6.99 | 1.77 | 1.78 | 3.05 | 2.68 |
| Interest coverage | 4.6 | 1.7 | 1.6 | -21.4 | -61.2 | -43.2 | -32.0 | -100.6 | -104.2 | — |
| Working capital | $477.0M | $475.7M | $264.2M | $115.1M | $265.6M | $524.2M | $64.7M | $40.2M | $65.4M | $34.0M |
| Invested capital | $766.8M | $165.1M | $53.8M | −$20.0M | $1.4M | −$44.1M | −$61.0M | −$44.7M | −$17.7M | −$9.0M |
| Tangible asset value | $648.0M | $221.6M | $159.7M | $57.8M | $236.4M | $518.6M | $37.8M | $23.2M | −$1.6M | −$1.6M |
| Net current asset value | $215.5M | $211.0M | $148.9M | $33.3M | $188.5M | $505.4M | $24.8M | $19.5M | −$4.1M | −$3.9M |
| Graham number | $15.82 | $2.13 | $1.44 | — | — | — | — | — | — | — |
| Graham net-net per share | $0.12 | $0.67 | $0.72 | $0.20 | $1.22 | $4.33 | $0.18 | $0.19 | −$0.14 | −$0.14 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $0 | $0 | $0 | — | $0 | $0 |
| Share buybacks (net) | $91.2M | $8.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.5% | 6.0% | 234.9% | 86.2% | 59.2% | 1.5% | 225.7% |
| Capex / depreciation | 0.88 | 0.16 | 0.00 | 0.03 | 0.81 | 0.95 | 0.46 | 1.02 | 0.03 | 5.46 |
| Stock-based compensation / revenue | 10.5% | 12.9% | 16.2% | 688.9% | 916.0% | 52,821.7% | 7,457.2% | 8,477.6% | 10,464.1% | 4,928.4% |
| R&D / revenue | 26.0% | 28.7% | 32.6% | 4,501.0% | 3,327.5% | 109,142.1% | 101,434.2% | 101,179.6% | 63,581.5% | 43,633.9% |
| SG&A / revenue | 37.7% | 46.9% | 52.5% | 3,428.5% | 1,914.9% | 70,953.9% | 9,886.2% | 13,657.2% | 14,423.1% | 8,289.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 128.8 | 100.0 | 39.9 | 91.0 | 37.9 | 0.0 | — | 244.3 | 230.3 | 323.2 |
| Days of inventory on hand | 427.7 | 712.6 | 514.3 | — | -10,905.6 | — | — | 36,578.8 | 20.8 | -24.1 |
| Days payables outstanding | 300.4 | 458.9 | 1,039.5 | 64,262.7 | 20,400.3 | 32,720.7 | 42,983.3 | 129,106.8 | 63.2 | 56.8 |
| Cash conversion cycle (days) | 256.0 | 353.8 | -485.3 | -80,427.3 | -31,268.0 | -32,720.7 | — | -92,283.6 | 187.9 | 242.3 |
| Receivables turnover | 2.83 | 3.65 | 9.15 | 4.01 | 9.63 | — | — | 1.49 | 1.58 | 1.13 |
| Payables turnover | 1.21 | 0.80 | 0.35 | 0.01 | 0.02 | 0.01 | 0.01 | 0.00 | 5.77 | 6.42 |
| Inventory turnover | 0.85 | 0.51 | 0.71 | — | — | — | — | 0.01 | 17.54 | — |
| Asset turnover | 0.75 | 0.73 | 0.89 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $217.4M | $90.1M | $25.5M | $694,500 | $694,500 | $0 | — | $101,734 | $96,160 | $134,936 |
| Average payables | $82.9M | $48.4M | $40.2M | $46.7M | $44.2M | $33.5M | $33.2M | $31.1M | $20.6M | $12.3M |
| Average inventory | $118.0M | $75.1M | $19.9M | −$11.8M | −$23.6M | — | — | $8.8M | $6.8M | −$5.2M |
| Intangibles / total assets | 0.0% | 0.1% | 0.2% | 0.4% | 0.2% | 0.1% | 0.5% | 1.0% | 1.6% | 2.9% |
Computed from TGTX's annual financial statements (latest annual report filed February 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TGTX valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), TG Therapeutics traded at 10.8 times earnings, against a 10-year median of 200.2. Based on the latest twelve months, the trailing P/E is 19.6 and the forward P/E is 25.9. TG Therapeutics earned a return on equity of 102.8% and a return on invested capital of 26.5% in fiscal 2025. It ended the year with $260.7 million of debt and $142.0 million in cash and short-term investments, net debt of $118.8 million. It returned $91.2 million to shareholders: $0 in dividends and $91.2 million in share buybacks. The share count rose 229.1% from 49.0M to 161.4M over 9 years.
See the TGTX income statement, the TGTX chart for price history, or the TGTX stock overview for the latest quote and news.
TGTX key metrics FAQ
What is TG Therapeutics's P/E ratio?
TG Therapeutics's trailing P/E ratio is 19.6 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 25.9. At the end of fiscal 2025 it was 10.8, compared with a 10-year median of 200.2.
What is TG Therapeutics's EV/EBITDA?
TG Therapeutics's enterprise value was 36.7 times EBITDA at the end of fiscal 2025 (enterprise value $4.9 billion, EBITDA $134.4 million); the current EV/EBITDA is 62.8.
What is TG Therapeutics's return on equity?
TG Therapeutics's return on equity (ROE) was 102.8% in fiscal 2025: net income of $447.2 million on average shareholders' equity of $435.2 million. ROE is high partly because years of buybacks have reduced equity on the balance sheet.
What is TG Therapeutics's ROIC?
TG Therapeutics's return on invested capital was 26.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does TG Therapeutics have?
TG Therapeutics had total debt of $260.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.40 and $118.8 million of net debt (0.88 times EBITDA).
Does TG Therapeutics buy back its shares?
Yes. TG Therapeutics spent $91.2 million on net share repurchases in fiscal 2025 Shares outstanding changed +0.7% over the year, to 161.4M..
What is TG Therapeutics's free cash flow yield?
TG Therapeutics generated -$25.0 million of free cash flow in fiscal 2025, a free cash flow yield of −0.5% on its market value at year-end ($4.8 billion).
What is TG Therapeutics's current ratio?
TG Therapeutics's current ratio was 4.10 at the end of fiscal 2025: current assets were 4.10 times current liabilities.